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Edited by Stuart FergusonAbstract We have evaluated the roles of key amino acids to the
action of the natural inhibitor chagasin of papain-family cysteine
peptidases. A W93A substitution decreased inhibitor aﬃnity for
human cathepsin L 100-fold, while substitutions of T31 resulted
in 10–100-fold increases in the Ki for cruzipain of Trypanosoma
cruzi. A T31A/T32A double mutant had increased aﬃnity for
cathepsin L but not for cruzipain, while the T31-T32 deletion
drastically aﬀected inhibition of both human and parasite pepti-
dases. These diﬀerential eﬀects reﬂect the occurrence of direct
interactions between chagasin and helix 8 of cathepsin L, inter-
actions that do not occur with cruzipain.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V.
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Open access under CC BY license.1. Introduction
Chagasin is a natural inhibitor of Clan CA, Family C1 cys-
teine peptidases (CP), which was identiﬁed in the protozoan
Trypanosoma cruzi, the causative agent of human Chagas
disease [1,2]. It is a single 110-residue polypeptide chain with
no sequence similarity to other known groups of CP inhibitors
and potently inactivates papain-like enzymes through the
formation of 1:1 tight–binding complexes. Chagasin-like
inhibitors which occur in other protozoa and bacteria [3] have
been designated as ICP (Inhibitor of Cysteine Peptidases), and
together comprise the chagasin family (Clan XI – Family I42)
[3,4].
Genetic evidence indicates that chagasin itself regulates the
activity of cruzipain, the major CP activity of T. cruzi. This
conclusion is based on the ﬁndings that T. cruzi lines that over-Abbreviations: Z-Phe-Arg-MCA, carbobenzoxy-phenylalanyl-arginyl-
7-amido-4-methylcoumarin; PBS, phosphate buﬀered saline; cruzain,
recombinant cruzipain truncated at the C-terminal extension; DTT,
dithiothreitol; EDTA, ethylenidiaminetetracetic acid disodium salt 2-
hydrate; E-64, L-trans-epoxysuccinylleucylamido-(4-guanidino) bu-
tane; IPTG, isopropyl-b-D-thiogalactopyranoside
*Corresponding author. Fax: +55 21 2280 8193.
E-mail address: anapaula@biof.ufrj.br (Ana Paula C.A. Lima).
0014-5793  2008 Federation of European Biochemical Societies. Published
doi:10.1016/j.febslet.2008.01.008express chagasin have an 80% decrease in active CPs, are less
capable to diﬀerentiate and are less infective to mammalian
cells in vitro [5].
The solution structures of chagasin and of Leishmania
mexicana ICP determined by NMR showed that the molecule
has an Ig-like fold and three exposed loop regions, which bear
evolutionarily conserved residues, located at one end of the
molecule [6,7]. These three key loops, L2 (residues 27–33),
L4 (residues 59–69) and L6 (residues 91–100) contain, respec-
tively: (i) the NPTTG motif; (ii) a conserved region bearing
two hydrophobic residues followed by GXGG; and (iii) the
RPW/F motif [6]. Studies of chemical shift perturbations upon
chagasin contact with cruzipain identiﬁed residues in L2, L4
and L6 as candidates to comprise chagasins binding-site to
target enzymes [6]. This hypothesis was reinforced by docking
of a high resolution crystal structure of chagasin to the high-
resolution structure of cruzain (truncated recombinant cruzi-
pain) [8]. The recent determination of the chagasin–falcipain2
[9] and chagasin–cathepsin L [10] complex structures revealed
that L2 is in close proximity to the peptidases catalytic triad
and that the conserved residues T31 and T32 of chagasin medi-
ate the formation of key hydrogen bonds with the peptidases,
mainly through water molecules. In contrast, the conserved
P30 seems to fulﬁll a structural role. The conserved residues
within L6 appear to make mainly hydrophobic interactions
with the peptidases, and could ultimately contribute to high
aﬃnity inhibition. These ﬁndings raised the question of the rel-
ative contributions of the conserved residues to chagasins
function as an inhibitor, the question that the present study
set out to address.2. Materials and methods
2.1. Site-directed mutagenesis
T. cruzi (Dm28c) chagasin, was cloned into the pQE30 expression
vector to produce a fusion with a 6X-Histidine tag. Mutants of chaga-
sin were obtained by site-directed mutagenesis using speciﬁc oligonu-
cleotides (Table 1). All plasmids were conﬁrmed by DNA sequencing.
2.2. Expression and puriﬁcation of recombinant chagasin variants
Overnight cultures of Escherichia coli M15/pRep4 containing the
various chagasin plasmids were diluted 20-fold in fresh LB medium
containing 50 lg/mL ampicillin and 25 lg/mL kanamicin and grown
for 1 h at 37 C followed by addition of 1 mM isopropyl-b-D-thioga-
lactopyranoside (IPTG) and incubation overnight at 16 C. The cells
were lysed by sonication in 50 mM Na2PO4, pH 8, 300 mM NaCl,by Elsevier B.V. Open access under CC BY license.
Table 1
Site-directed mutagenesis of chagasin
Mutation Construct Oligonucleotide Sequence
W93A pGL1199 OL1695 50-TTTACATGCGCCCGGCGACAGGAGCTTCGC-3 0
OL1696 50-GCGAAGCTCCTGTCGCCGGGCGCATGTAAA-3 0
Y89A pGL1118 CHAGY1 50-ATTCTCACTGCCATGCGCCCG-30
CHAGY2 50-CGGGCGCATGGCAGTGAGATT-30
Y89S pGL1120 CHAGY3 50-ATTCTCACTTCCATGCGCCCG-30
CHAGY4 50-CGGGCGCATGGAAGTGAGATT-30
Y89F pGL1119 CHAGY5 50-ATTCTCACTTTCATGCGCCCG-30
CHAGY6 50-CGGGCGCATGAAAGTGAGATT-30
P30A pGL1194 OL1679 50-GCTTCCCAGCAATGCCACCACCGGGTTC-30
OL1680 50-GAACCCGGTGGTGGCATTGCTGGGAAGC-30
T31A pGL1209 OL1681 50-CCAGCAATCCCGCCACCGGGTTCG-30
OL1682 50-CGAACCCGGTGGCGGGATTGCTGG-3 0
T31S pGL1299 OL1851 50-CCAGCAATCCCTCCACCGGGTTCG-30
OL1852 50-CGAACCCGGTGGAGGGATTGCTGG-30
T31V pGL1298 OL1849 50-CCAGCAATCCCGTCACCGGGTTCG-30
OL1850 50-CGAACCCGGTGACGGGATTGCTGG-30
T31Y pGL1210 OL1683 50-CTTCCCAGCAATCCCTACACCGGGTTCGCGTG-3 0
OL1684 50CACGCGAACCCGGTGTAGGGATTGCTGGGAAG-30
T32A pGL1211 OL1685 50-GCAATCCCACCGCCGGGTTCGCGT-30
OL1686 50-ACGCGAACCCGGCGGTGGGATTGC-3 0
T32S pGL1195 OL1687 50-AGCAATCCCACCTCCGGGTTCGCGTG-30
OL1688 50-CACGCGAACCCGGAGGTGGGATTGCT-30
T32E pGL1197 OL1691 50CCCAGCAATCCCACCGAGGGGTTCGCGTGGTATTTT-3 0
OL1692 50AAAATACCACGCGAACCCCTCGGTGGGATTGCTGGG-3 0
T32Y pGL1198 OL1693 50-CCAGCAATCCCACCTACGGGTTCGCGTGGT-3 0
OL1694 50-ACCACGCGAACCCGTAGGTGGGATTGCTGG-3 0
T32V pGL1196 OL1689 50-CAGCAATCCCACCGTCGGGTTCGCGTGG-30
OL1690 50-CCACGCGAACCCGACGGTGGGATTGCTG-30
T31A/T32A pGL1258 OL1776 50-CCCAGCAATCCCGCCGCCGGGTTCGCGTGG-3 0
OL1777 50-CCACGCGAACCCGGCGGCGGGATTGCTGGG-30
DT31–T32 pGL1259 OL1778 50-CAGCTTCCCAGCAATCCCGGGTTCGCGTGGTAT-30
OL1779 50-ATACCACGCGAACCCGGGATTGCTGGGAAGCTG-30
The pairs of oligonucleotides used to perform site-directed mutagenesis are listed with the respective amino acid substitution. The targeted mutations
are marked in bold. T. cruzi Dm28c chagasin gene was used as a template in PCR reactions. The mutations were conﬁrmed by DNA sequencing.
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at 10000 · g and ﬁltered. The sample was applied to a Metal Chelate
Ni+ Column (BioCAD, BioSystems). The resin was washed with
50 mM Na2PO4, pH 7.9, 300 mM NaCl, 50 mM imidazole and the re-
combinant proteins were eluted in the same buﬀer supplemented with
500 mM imidazole. The eluted samples were further puriﬁed by HQ
Ion Exchange in 50 mM Tris–HCl, pH 7, 5 mM ethylenidiaminetetr-
acetic acid disodium salt 2-hydrate (EDTA), eluted in the same buﬀer
over a 1 M NaCl gradient and the fractions were pooled. The purity of
the samples was analysed by 14% SDS–PAGE, followed by Coomassie
staining.
2.3. Heat stability
Wild type chagasin and the variants were diluted to 90 lg/ml in
20 mM phosphate buﬀer, 150 mM NaCl pH 7.2 (PBS) and incubated
in a water bath at 70 C for 20 min or kept on ice. The inhibitors were
subsequently incubated at 2 lg/ml with 0.07 nM of papain in 50 mM
Na2PO4, pH 6.5, 200 mM NaCl, 5 mM EDTA, 2.5 mM dithiothreitol
(DTT) for 5 min at room temperature. Enzyme activity was subse-quently monitored by the hydrolysis of 5 lM of carbobenzoxy-phenyl-
alanyl-arginyl-7-amido-4-methylcoumarin (Z-Phe-Arg-MCA). Initial
velocities were determined from linear regression on the substrate
hydrolysis curves and used to calculate the percentage of inhibition
in relation to controls kept on ice.
2.4. Enzyme inhibition assays
Concentrations of inhibitory chagasin were determined by titration
with papain, which had been previously titrated with E-64 [11]. Diﬀer-
ent volumes of the recombinant chagasin and 100 nM papain solution
and were incubated for 30 min at room temperature in RB buﬀer
(50 mM Na2PO4, pH 6.5, 200 mM NaCl, 5 mM EDTA, 2.5 mM
DTT). Aliquots of 5 lL of the incubation were diluted in 1 mL of
the same buﬀer and residual enzyme activity was measured by the
hydrolysis of 5 lM Z-Phe-Arg-MCA. Substrate hydrolysis was moni-
tored in a F4500 Hitachi ﬂuorimeter at 380 nm excitation, 440 nm
emission and the initial velocities were calculated by linear regression.
The determination of the equilibrium constants for dissociation (Ki)
were performed in RB buﬀer at 25 C, as described for tight inhibitors
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cathepsin L (Calbiochem) were incubated with diﬀerent chagasin con-
centrations for 15 min at room temperature and the residual velocities
were measured by the hydrolysis of 5 lM Z-Phe-Arg-MCA. The Kiapp
values were determined from the slope of a plot of [I]0/1  a, against 1/
a, where a = Vi/V0. Ki constants were calculated from Kiapp values
using the KM values of 1.5 lM, 2.5 lM, 60 lM, for cruzipain, cathep-
sin L, and papain, respectively. The Ki values of some of the mutants
with cathepsin L were further conﬁrmed by the Dixon method in con-
tinuous assays using [S]> KM.
2.5. Homology based modeling
Models of the chagasin–peptidase complexes were built using Mod-
eller 9.1 [14] based on the coordinates of the chagasin–falcipain2 com-
plex (9; PDB 2oul). For cruzain, PDB entries 1aim, 1me4 and 1me3
were aligned with falcipain 2 using Modellers structure based align-
ment algorithm to serve as templates for the complex.3. Results and discussion
3.1. Production of chagasin variants
We used the ﬁndings from the studies of chagasin docking to
cruzipain and chemical shift perturbation as a base to guide
the site-directed mutagenesis [6,8]. The solution structure of
chagasin suggested that the spatial arrangement of Loop2
(L2) might be inﬂuenced by the conserved Y89 residue, which
is present on the b7 strand in close proximity to L2, and
protrudes towards S28 [6]. Thus we selected this residue and
also residues P30, T31, T32, composing the conserved NPTTG21
L4 6
T. cruzi          MSHKV----TKAHNGATLTVAVGELVEI
T. brucei         MSHNL---FTEEDNNKTIRMVIGETFTI
L. mexicana       MIAPL----SVKDNDKWVDTHVGKTTEI
L. major          MQPKMTAPLTMKDNNKCLSVRVGSTLEI
T. cruzi          FP-PDSK--------LLGAGGTEHFHVT
T. brucei         NNRAPHDNHKNHRRLLVGAGGTMVLEVK
L. mexicana       TPTPSST-------PMVGVGGIYVVLVK
L. major          TPKPVSG-------SMVGAGGSYTVFVK
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Fig. 1. Chagasin residues targeted for mutagenesis. (A) Sequence alignment
(AJ548776) and T. brucei ICP (AJ548777). The secondary structure is assig
residues in loops L2, L4 and L6 are coloured blue, magenta, and green. The r
of the modeled interface between chagasin (beige) and cruzain (grey). Ch
respectively. Residues responsible for direct peptidase recognition and the pe
study are labeled and highlighted as fatter sticks.motif (L2), and the conserved W93 (L6) as targets for amino
acid replacement in chagasin variants (Fig. 1A). The relative
position of the residues selected for mutagenesis at the inhibi-
tor–peptidase interface is shown in Fig. 1B. The relative
importance of the side chains of T31 and T32 was investigated
by studying variants bearing substitutions to charged, apolar
and hydrophobic residues. We also addressed the importance
of the length of L2 by the generation of a mutant devoid of res-
idues T31 and T32 (see Table 1). All variants were generated
using similar methods and SDS–PAGE of the puriﬁed proteins
under reducing conditions showed that all variants had mobil-
ities similar to that of chagasin (data not shown).
Chagasin is highly thermo-stable, retaining its inhibitory
activity even after boiling [1,5]. We performed temperature sta-
bility assays to examine whether the introduced amino acid
substitutions caused detrimental eﬀects on the tertiary struc-
ture and to stability of chagasin mutants, as previously re-
ported to occur with cystatin C, another CP inhibitor [15].
No major eﬀect on the inhibitory activity of chagasin or most
of the variants was detected by treatment at 70 C (Fig. 2),
indicating that the mutations did not signiﬁcantly aﬀect the
overall structure of the proteins. The T32Y variant had 20%
loss of inhibitory activity, suggesting that minor structural/
folding alterations had resulted from the mutation introduced.
The Y89S and T31Y variants kept on ice were about 40% less
active than chagasin, even when tested at large excess over pa-
pain, indicating that they had lower aﬃnity for this CP. TheL23 4 5
L67 8
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Fig. 2. Thermo-stability properties of chagasin mutants. (A) Chagasin
variants were submitted to high temperatures and subsequently tested
for inhibitory activity to evaluate if the mutations introduced caused
alterations in their folding state. The inhibitory activity of variants
kept on ice was measured in parallel as a control. Chagasin variants
were kept on ice (clear bars) or incubated at 70 C for 20 min (dark
bars). The samples were subsequently incubated with papain for 5 min
and the residual activity was measured by addition of Z-Phe-Arg-
MCA. The experiment was performed twice independently and the
variation was below 10%. The graph represents one experiment. The
percentage of inhibition was calculated considering the activity of
untreated papain as 100%. 1, T32Y; 2, T32S; 3, Y89F; 4, T31V; 5,
T31S; 6, T32E; 7, wild type; 8, Y89S; 9, T32A; 10, T31Y; 11, T32V; 12,
W93A; 13, P30A; 14, T31A/T32A. (B) NMR spectra of the chagasin
variant DT31–T32. Comparison of 15N HSQC spectra recorded at
600 MHz (1H) and 298 K, of wild type chagasin (black) with variant
DT31–T32 (blue), indicating that this variant is properly folded.
Table 2
Ki values for chagasin against T. cruzi cruzipain and human cathepsin
L
Substitution Region Cruzipain Cathepsin L
Ki (pM)
Chagasin – 7.6 ± 0.67 7.3 ± 1.2
W93A L6 31 ± 3.5 825 ± 79
Y89S b7-strand 25 ± 3.1 ND
Y89F b7-strand 20 ± 0.8 ND
P30A L2 20 ± 1.7 45 ± 7.3
T31A L2 317 ± 26 3.9 ± 0.7
T31V L2 70 ± 4.3 9.7 ± 1.1
T31S L2 11 ± 0.6 4.9 ± 0.6
T31Y L2 747 ± 44 6.8 ± 0.9
T32A L2 16 ± 1.1 14 ± 1.8
T32S L2 20 ± 1.9 32 ± 2.2
T32E L2 11 ± 2.0 ND
T32Y L2 16 ± 0.7 2.7 ± 0.2
T32V L2 193 ± 13 20 ± 0.8
T31A/T32A L2 1065 ± 116 1.8 ± 0.4
DT31–T32 L2 5868 ± 29 2200 ± 17
Equilibrium constants for dissociation (Ki) of complexes between
cysteine peptidases and chagasin variants. The results are represented
as mean values from three independent Ki measurements. The enzymes
were assayed for inhibition as described in methods. N.D., not deter-
mined. The values are mean of three independent Ki determina-
tions ± S.E. The conditions of hydrolysis: 50 mM Na2HPO4, 100 mM
NaCl, 5 mM EDTA, pH 6.5, 5% DMSO, 2.5 mM DTT, at 28 C.
488 F.C.G. dos Reis et al. / FEBS Letters 582 (2008) 485–490variants Y89A and DT31-T32 had no inhibitory activity
against papain. Analysis of their NMR spectra revealed that
the Y89A mutant was partially or completely unfolded (not
shown), it was thus excluded from further investigation. How-
ever, the DT31-T32 variant remained folded (Fig. 2B), suggest-
ing its lack of inhibitory activity against papain was not due to
loss of conformation.3.2. Enzyme inhibition properties of chagasin variants
The equilibrium constants for dissociation (Ki) of the vari-
ants and chagasin from complexes with the T. cruzi CP cruzi-
pain and human cathepsin L were determined from continuous
assays (Table 2). In order to have an accurate estimation of the
amount of active inhibitor present, the preparations were
titrated against papain. The Ki value of recombinant His-
tagged wild type chagasin with cruzipain and papain were
essentially the same as reported for native chagasin puriﬁed
from T. cruzi [1], so we performed all kinetic assays with
His-tagged mutants.
The substitution of Y89, which caps the hydrophobic core of
chagasin in the 7th b-strand, to either S or F had no impact in
the inhibition of cruzipain. In contrast, Y89S was 60-fold less
potent than the wild type protein (designated WT) for the
inhibition of papain (WT Ki = 5 ± 0.7 pM; Y89S Ki = 316 ±
17 pM), while the Ki of the Y89F variant was unchanged.
These results suggest that the bulky hydrophobic side chain
of Y89 is important for chagasins inhibitory function against
papain, while it is unnecessary for the inhibition of cruzipain.
The crystal structure of chagasin indicates that residues Y89,
D99 and E101 make contact with Loop4 (L4), although such
contacts are not observed in the peptidase–chagasin complexes
[8–10]. In addition, water molecule-mediated hydrogen bond-
ing between the hydroxyl group of Y89 and G66 (L4) and
between Y89, S62 and T32 (L2) were observed, suggesting that
Y89 contributes to maintaining the relative orientations of L2
and L4 [9,10]. Although the result with Y89F indicates that the
hydrogen bonding is dispensable for the maintenance of
chagasins tertiary structure, the ﬁnding that the Y89A variant,
but not Y89S, was unfolded suggests that in the absence of a
bulky residue at position 89 the H-bonding mediated by serine
F.C.G. dos Reis et al. / FEBS Letters 582 (2008) 485–490 489becomes important in preventing the collapse of the tertiary
structure.
Intriguingly, the W93A mutant inhibited cruzipain in the
same range as WT, but displayed 100-fold less aﬃnity for
cathepsin L. This suggests that interactions with residues of
L6 might be selectively important for chagasins inhibition
of this host peptidase. Residues R91/P92/W93 (RPW) in L6
form an apparently critical tripartite peptidase recognition
motif, as recently described in detail for the interaction with
cathepsin L [10]. In the complex, W93 resides within a hydro-
phobic cluster with the peptidase residues. This causes R91 to
lie in extended conformation sandwiched between W93 and
F34 (L2), such that R91 hydrogen bonds with N18 of cathep-
sin L. It seems likely that removal of W93 disturbed the R91–
N18 interaction, and that this is important to ﬁx chagasin
tightly to cathepsin L.
The functional characterization of a large number of vari-
ants bearing substitutions in L2 showed that this domain is
generally important for the inhibitory function of chagasin.
Interestingly, the relative contribution of the diﬀerent residues
varied with the target enzyme, and the main conclusions that
can be drawn from the inhibition assays are as follows.
The mutation P30A caused a sixfold increase in the Ki for
cathepsin L and showed little change in aﬃnity for cruzipain.
The structure of chagasin revealed that this residue apparently
contributes to the conformation of L2 through packing against
Y58 of chagasins hydrophobic core. Based on this, the muta-
tion to alanine was expected to result in weaker binding to the
peptidases due to looser packing of L2 with the more ﬂexible
L2 loop incurring a greater entropic penalty in becoming ﬁxed
in the complex. However, greater ﬂexibility of L2 in the com-
plex, permitted by the mutation, might make this change
rather neutral resulting in only a small change of aﬃnity, as
is observed.
The evolutionarily conserved T31 plays a pivotal role in the
inhibition of cruzipain, while it is of relatively low importance
for the inhibition of cathepsin L (Table 2). In the chagasin–
cathepsin L complex, T31 contacts the peptidase active site
cysteine via a water mediated hydrogen bond and helps to de-
ﬁne the conformation of L6 such that it cannot be attacked by
the peptidase [15]. However, mutations of this residue that re-
move its bulk (T31S), its side chain hydroxyl (T31V) or bothFig. 3. Illustration of the diﬀerences in the interaction of chagasin with cystei
the ‘‘prime’’ end of the active site coloured as in Fig. 1 with the peptidase ‘‘
cathepsin L complex (PDB:2ndq) illustrating the more extensive interaction s(T31A), or that increase its bulk (T31Y) have virtually no eﬀect
on chagasins binding to cathepsin L. Our suggested explana-
tion for this is that T31 is eﬀectively partially surface exposed
and surrounded by ordered water molecules in both deter-
mined peptidase complexes. Thus removal of its sidechain bulk
could be compensated by additional water molecules, or a
bulkier side chain accommodated by displacing them. In con-
trast, the removal of the side chain in T31A or the introduction
of a bulkier chain in T31Y resulted in a 40–100-fold decrease in
aﬃnity for cruzipain, indicating that the contacts made by T31
are more critical for this enzyme (Table 2). Given the similarity
between the peptidases in this region, these diﬀerent eﬀects
must mean that either there are additional interactions yet to
be realised, or that there are signiﬁcantly diﬀerent dynamic/
entropic properties of the interface in the two complexes.
The conserved T32 also contributes to the binding, but to a
lesser extent. Removal of the side chain in T32A, the increase
of its length and addition of negative charge in T32E, or the
introduction of a bulky side chain in T32Y, had no eﬀect on
the aﬃnity for cruzipain (Table 2). In contrast, removal of
the hydroxyl group in T32V caused a signiﬁcant increase in
the Ki. T32 has well deﬁned roles satisfying intra-molecular
hydrogen bonds and deﬁning the conformation of L2. How-
ever, our ﬁndings that this residue is highly tolerant of substi-
tution suggest that changes in the side chain can be easily
accommodated by involving additional water molecules or dis-
placing them. Again, cruzipain is more sensitive to alterations
of T32, but of the substitutions tested only removing the
hydrogen bonding potential while maintaining the bulk of
the side chain (T32V) had a large eﬀect.
The roles of the conserved threonine residues in L2 were fur-
ther addressed by the double mutation T31A-T32A. This var-
iant displayed 140-fold decrease in aﬃnity for cruzipain and a
subtle decrease in the aﬃnity for papain (Ki = 27 ± 1.5 pM).
Interestingly, its aﬃnity for cathepsin L was slightly increased
(Table 2). We generated a mutant devoid of T31 and T32 in
order to evaluate the importance of the length of L2. This var-
iant lacked inhibitory activity against papain and showed a
great reduction in potency of inhibition of cathepsin L
(300-fold) and cruzipain (700-fold). This suggests that the
length of L2 is generally important for inhibitor function,
regardless of the target enzyme.ne peptidases. (A) The chagasin–cruzain interaction model viewed from
helix 8’’ region highlighted in red. (B) The same view of the chagasin–
urface provided by the peptidase on the ‘‘helix 8’’ lip of the active site.
490 F.C.G. dos Reis et al. / FEBS Letters 582 (2008) 485–490We also compared the chagasin–cathepsin L complex with a
homology model of the chagasin–cruzain complex in an at-
tempt to explain the diﬀerent behaviour of the variants with
the two peptidases (Fig. 3). In the chagasin–cathepin L com-
plex, P92 seems to ﬁx the relative orientations of R91 and
W93 in L6 and makes hydrophobic contacts with F145 and
L144 of the peptidase (Fig. 3B) [10]. In cruzain, this region
adopts a diﬀerent conformation that protrudes less and is dec-
orated with less hydrophobic residues (Fig. 3A), indicating
that cathepsin L has more options to maintain binding when
the favourable contribution from T31 is removed. Since these
options are not available for cruzain, interaction with T31
might be more crucial in maintaining cruzain–chagasin tight
complexes.
In contrast, the W93A mutation had a small eﬀect on bind-
ing to cruzipain but a much greater eﬀect on interaction with
cathepsin L. Residue R91 of L6 makes a hydrogen bond with
cathepsin L N18, while in cruzain, residue 18 is an aspartate
which can make an energetically more favourable ionic inter-
action. A possible explanation for our observation is that
cathepsin L, lacking the ionic interaction with D18 as in cruz-
ain, is much more dependent on the supporting role of W93.
Collectively, these data indicate that the structural basis for
the function of chagasin as a high-aﬃnity inhibitor of papain-
like CPs varies according to the target enzyme, with main
contributions of T31 located on L2 for the inhibition of the
endogenous CP of the parasite and of W93 located on L6
for the inhibition of host cathepsin L. Structural analyses of
the complexes of chagasin with additional peptidases will bring
further understanding of the diﬀerences in its mode of inhibi-
tion of target peptidases.
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